The business transformation (manufacturing sale + royalty monetization) removes near-term financing overhang and positions MGNX for pipeline catalysts in mid-2026. Traders should watch for MGC026 Phase 1 data in mid-2026, which could be a major inflection point. The stock may re-rate on reduced dilution risk and extended runway.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $4.16entry
- T+1 · 6mo ago 0.00%α −0.01% · $4.16
- T+5 · 6mo ago +1.92%α +2.64% · $4.24
- T+20 · 5mo ago −4.81%α −3.95% · $3.96
- T+60 · 3mo ago −1.92%α −5.51% · $4.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consensus of -$0.57 (actual -$0.58). More importantly, the company announced a manufacturing divestiture and ZYNYZ royalty monetization expected to provide up to $202.5M in non-dilutive capital, extending cash runway through 2028 and reducing near-term financing risk.
Key Financial Metrics
Key Facts
- Revenue grew 57% YoY to $20.8M driven by contract manufacturing and royalty revenue
- Net loss narrowed to $36.8M from $41.0M in Q1 2025
- EPS of -$0.58 vs consensus -$0.57 (in line)
- Manufacturing operations divestiture to Bora Pharmaceuticals for $122.5M upfront
- Expanded ZYNYZ royalty monetization with Sagard: $60M received plus up to $20M milestone
- Cash runway extended through 2028, up from late 2027 prior guidance
- ADC pipeline on track for multiple data readouts in mid-2026 (MGC026, MGC028, lorigerlimab)
- Lorigerlimab showed 25% objective response rate in CCGC; ovarian cancer program halted
Financial Impact
Manufacturing divestiture and royalty monetization provide up to $202.5M in non-dilutive capital, significantly reducing dilution risk and extending cash runway through 2028.
Risk Factors
- Manufacturing divestiture closing conditions (expected Q3 2026) - transaction risk
- Pipeline data readouts are binary events - clinical failure could erase value
- Partial clinical hold on lorigerlimab LINNET study remains unresolved
- Sagard milestone payment dependent on ZYNYZ 2026 sales performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000040 |
| Document: mgnx-20260513.htm | 0001125345-26-000040 |
| Document: 0001125345-26-000040-index-headers.html | 0001125345-26-000040 |
| Document: 0001125345-26-000040-index.html | 0001125345-26-000040 |
| Document: 0001125345-26-000040.txt | 0001125345-26-000040 |
| 8-K Data (Synthetic) | 0001125345-26-000040 |
Track record
21 reports on MGNX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers